Transparency Standards for Diabetes Performance Measures

被引：18

作者：

Aron, David ^{[1
,2
]}

Pogach, Leonard ^{[3
,4
]}

机构：

[1] Louis Stokes Cleveland VA Med Ctr, Educ Off 14W, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Cleveland, OH 44106 USA

[3] New Jersey Vet Hlth Adm Healthcare Syst, E Orange, NJ USA

[4] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 301卷 / 02期

关键词：

TARGETS;

D O I：

10.1001/jama.2008.930

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：210 / 212

页数：3

共 15 条

[1]

*AG HEALTHC RES QU, ASS QUAL CAR DIAB

[2] ACCP evidence-based guideline development - A successful and transparent approach addressing conflict of interest, funding, and patient-centered recommendations [J].

Baumann, Michael H. ;

Lewis, Sandra Zelman ;

Gutterman, David .

CHEST, 2007, 132 (03) :1015-1024

[3]

*BRIDG EXC, DIAB CAR LINK

[4]

*BURS, NAT DIAB CALL ACT BL

[5] Influence of industry on renal guideline development [J].

Coyne, Daniel W. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (01) :3-7

[6] The Diabetes Quality Improvement Project - Moving science into health policy to gain an edge on the diabetes epidemic [J].

Fleming, BB ;

Greenfield, S ;

Engelgau, MM ;

Pogach, LM ;

Clauser, SB ;

Parrott, MA .

DIABETES CARE, 2001, 24 (10) :1815-1820

[7]

Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743

[8]

Hayward RA, 2007, AM J MANAG CARE, V13, P126

[9]

*NAT COMM QUAL ASS, QUAL MATT

[10]

*NAT QUAL FOR, NAT VOL CONS STAND 2

← 1 2 →